Scholarlink

Background <p>Gastric cancer (GC) has poor prognosis due to distant metastasis with ovarian metastasis (OM) occurring in 5–10% of female patients and survival limited to 7–14 months. No standard treatment exists. This review analyzes global research and trends in OM management.</p> Methods <p>Publications on OM in GC (1991–2024) were retrieved from the Web of Science Core Collection. Bibliometric analysis of 324 articles was performed using CiteSpace and VOSviewer.</p> Results <p>Three main themes emerged: (1) diagnosis and pathology characteristics of OM, (2) treatment and management, and (3) clinical features in special populations, such as pregnancy.</p> Conclusion <p>Research hotspots include multidisciplinary treatment (MDT), diagnostic tumor markers (e.g., CA125, CA19–9, and carcinoembryonic antigen (CEA)), imaging (e.g., MRI, ultrasound), and novel approaches such as immunotherapy and targeted therapy (Microsatellite Instability-High (MSI - H), Tumor Mutational Burden-High (TMB - H). Future directions call for multicenter clinical trials and interdisciplinary collaboration to improve patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mapping the landscape of ovarian metastases of gastric cancer: insights, trends, and emerging perspectives

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月9日

查看全文
  • Liping Wang,
  • Tong Fu,
  • Yuqing Chen,
  • Xu Zhang

摘要

Background

Gastric cancer (GC) has poor prognosis due to distant metastasis with ovarian metastasis (OM) occurring in 5–10% of female patients and survival limited to 7–14 months. No standard treatment exists. This review analyzes global research and trends in OM management.

Methods

Publications on OM in GC (1991–2024) were retrieved from the Web of Science Core Collection. Bibliometric analysis of 324 articles was performed using CiteSpace and VOSviewer.

Results

Three main themes emerged: (1) diagnosis and pathology characteristics of OM, (2) treatment and management, and (3) clinical features in special populations, such as pregnancy.

Conclusion

Research hotspots include multidisciplinary treatment (MDT), diagnostic tumor markers (e.g., CA125, CA19–9, and carcinoembryonic antigen (CEA)), imaging (e.g., MRI, ultrasound), and novel approaches such as immunotherapy and targeted therapy (Microsatellite Instability-High (MSI - H), Tumor Mutational Burden-High (TMB - H). Future directions call for multicenter clinical trials and interdisciplinary collaboration to improve patient outcomes.